KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBITDA: 2009-2025

Historic EBITDA for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$20.1 million.

  • Biomarin Pharmaceutical's EBITDA fell 123.97% to -$20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $461.3 million, marking a year-over-year increase of 27.21%. This contributed to the annual value of $484.2 million for FY2024, which is 160.65% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported EBITDA of -$20.1 million as of Q3 2025, which was down 111.38% from $176.8 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's EBITDA peaked at $176.8 million during Q2 2025, and registered a low of -$65.9 million during Q4 2021.
  • Moreover, its 3-year median value for EBITDA was $83.9 million (2024), whereas its average is $89.2 million.
  • In the last 5 years, Biomarin Pharmaceutical's EBITDA spiked by 1,060.04% in 2023 and then plummeted by 123.97% in 2025.
  • Biomarin Pharmaceutical's EBITDA (Quarterly) stood at -$65.9 million in 2021, then skyrocketed by 80.13% to -$13.1 million in 2022, then soared by 308.43% to $27.3 million in 2023, then skyrocketed by 491.69% to $161.4 million in 2024, then crashed by 123.97% to -$20.1 million in 2025.
  • Its last three reported values are -$20.1 million in Q3 2025, $176.8 million for Q2 2025, and $143.2 million during Q1 2025.